post-injection deliriumsedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, ii investigations of mechanismpost-injection deliriumsedation综合症与奥氮平治疗的精神分裂症患者长效针剂,二世的调查机制.pdfVIP

post-injection deliriumsedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, ii investigations of mechanismpost-injection deliriumsedation综合症与奥氮平治疗的精神分裂症患者长效针剂,二世的调查机制.pdf

  1. 1、本文档共10页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  5. 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  6. 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  7. 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  8. 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
post-injection deliriumsedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, ii investigations of mechanismpost-injection deliriumsedation综合症与奥氮平治疗的精神分裂症患者长效针剂,二世的调查机制

McDonnell et al. BMC Psychiatry 2010, 10:45 /1471-244X/10/45 R E S E A R C H A R T I C L E Open Access Research article Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism 1 1 2 1 1 1 David P McDonnell* , Holland C Detke , Richard F Bergstrom , Prajakti Kothare , Jason Johnson , Mary Stickelmeyer , Manuel V Sanchez-Felix1 1 1 , Sebastian Sorsaburu and Malcolm I Mitchell Abstract Background: Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections ( 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed post-injection delirium/sedation syndrome (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Methods: Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted

您可能关注的文档

文档评论(0)

xyz118 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档